Karyopharm Therapeutics, Inc. (KPTI) was a big mover last session, as the company saw its shares surge 14% on the day. This rally higher can be attributable to solid volume too with far more shares changing hands than in a normal session. This continues the most recent uptrend of the company, as the stock is now up 30.6% in the past one-month time frame.
Over the last 30 days, Karyopharm Therapeutics did not witness any estimate revision and the Zacks Consensus Estimate has remained unchanged. However, the recent price action is encouraging, so make sure to keep a close watch on this firm in the near future.
Karyopharm Therapeutics currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.
Some other players in the healthcare industry include Alexion Pharmaceuticals, Inc. (ALXN), with a Zacks Rank #1 (Strong Buy) along with Biogen Idec Inc. (BIIB) and Cambrex Corporation.(CBM) holding a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
KARYOPHARM THERAPEUTICS INC (KPTI): Free Stock Analysis Report
ALEXION PHARMACEUTICALS INC (ALXN): Free Stock Analysis Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis Report
CAMBREX CORP (CBM): Free Stock Analysis Report
Zacks Investment Research
- Finance Trading
- Personal Investing Ideas & Strategies